However, the high failure rate of leaddrug candidates that targeted BACE-1 highlighted the necessity ofidentifying alternative targets to solve the puzzle of AD., Targeting the initial stage of amyloid β-production, the BACE-1inhibitor provides an effective way of disease modification and addressesone of the primary causes of AD. Here, BACE1 is linked to Alzheimer disease.